Bristol Myers Squibb Says FDA Accepts NDA For Mezigdomide In Combination With Carfilzomib And Dexamethasone In Patients With RRMM; PDUFA Date May 13, 2027

Loading news article.

Bristol Myers Squibb Says FDA Accepts NDA For Mezigdomide In Combination With Carfilzomib And Dexamethasone In Patients With RRMM; PDUFA Date May 13, 2027 | WAPE

Bristol Myers Squibb Says FDA Accepts NDA For Mezigdomide In Combination With Carfilzomib And Dexamethasone In Patients With RRMM; PDUFA Date May 13, 2027

Article summary

Related companies

Comments —